Evidence – Human-Relevant Safety NAMs for Translational Confidence & Therapeutic Index in Oncology Drug Development

• Human-relevant target organ NAMS can improve translation beyond traditional in vivo models, enabling more predictive assessment of specific safety risks
• A bone marrow MPS enables assessment of drug-induced marrow suppression for oncology monotherapies and combination therapies
• Bone marrow MPS integrated with quantitative systems toxicology modelling supports reliable prediction of patient hematologic effects for oncology therapeutics

Speakers:

Sonja Gill

Director, Oncology Safety Combinations, Clinical Pharmacology & Safety Sciences

AstraZeneca